- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02601404
REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)
Current drug-eluting stents (DES) has demonstrated excellent clinical outcomes in patients with coronary artery disease. However, a continued risk of clinical events even several years after the procedure is reported. Stent platform or polymer-associated inflammation may play a role.
Bioresorbable scaffold (BRS) is known to disappear 2 to 3 years after the implantation, which may result in the more favorable very long-term clinical outcomes compared with metallic stents. The initial clinical experiences of BRS in relatively simple lesion subsets were comparable to DESs.
BRS, however, is limited by the disadvantageous mechanical characteristics such as thick strut and the risk of fracture by overdilation. There is concern that BRS is less optimal for complex lesion subsets such as bifurcation lesions, calcified tortuous lesions, or diffuse long lesions. Real world registry is needed to test the feasibility and safety of BRS in these complex lesion subsets.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
-
Seoul, Korea, Republiken av, 135-710
- Rekrytering
- Cardiac and Vascular Center; Samsung Medical Center
-
Kontakt:
- Hyeon-Cheol Gwon, Professor
- Telefonnummer: 82234103419
- E-post: hc.gwon@samsung.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Subject must be between 19 and 70 years old.
- Patients with a significant lesion in a de novo coronary artery: a percent diameter stenosis (DS) 50% with 1) a positive history of recurrent angina pectoris; (2) objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent); or (3) abnormal results of any invasive functional diagnostic test (eg, fractional flow reserve) or a percent DS ≥70% even in the absence of the above-mentioned ischemic signs or symptoms.
- Patients are scheduled for coronary intervention
- He/she or his/her legally authorized representative provides written informed consent
Exclusion Criteria:
- Experience of cardiopulmonary resuscitation
- Cardiogenic shock
- Expected survival less than 2 years
- Pregnancy or breast feeding
- Opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Övrig
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Bioresorbable Scaffold
Patients receiving percutaneous coronary intervention (PCI) for coronary artery disease using Absorb™(Abbott Vascular)
|
The implantation procedure of an Absorb™ is similar to a metallic stent.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
cardiac death
Tidsram: 2 years
|
Target vessel failure (TVF) of cardiac death, myocardial infarction (MI) attributed to the target vessel, and target vessel revascularization (TVR)
|
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Device success
Tidsram: maximum of 7 days
|
Successful delivery and deployment of the study scaffold at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable).
|
maximum of 7 days
|
Procedural success
Tidsram: maximum of 7 days
|
Achievement of final in-scaffold residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat target lesion revascularization (TLR) during the hospital stay (maximum of 7 days).
|
maximum of 7 days
|
Target vessel failure (TVF)
Tidsram: 1, 3, and 5 years
|
cardiac death, target vessel MI, or TVR
|
1, 3, and 5 years
|
Each component of Target vessel failure (TVF)
Tidsram: 1, 2, 3 and 5 years
|
Cardiac death,Vascular death,Non-cardiovascular death,Myocardial Infarction (MI)
|
1, 2, 3 and 5 years
|
Target lesion failure
Tidsram: 1, 2, 3 and 5 years
|
Target lesion failure of cardiac death, MI attributed to the target vessel, and Target Lesion Revascularization(TLR). TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.
The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion, which includes upstream and downstream branches and the target lesion itself.
|
1, 2, 3 and 5 years
|
Definite or probable stent thrombosis
Tidsram: 1, 2, 3 and 5 years
|
1, 2, 3 and 5 years
|
|
Periprocedural enzyme elevation
Tidsram: 1, 2, 3 and 5 years
|
1, 2, 3 and 5 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2015-07-163
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Akuta kranskärlssyndrom
-
IRCCS Policlinico S. DonatoRekryteringAnomalous aortic origin of the coronary artery (AAOCA)Italien
-
Biotronik AGAvslutadde Novo Lesions in Native coronary arteriesNederländerna, Schweiz, Tyskland, Belgien
-
Osaka General Medical CenterAvslutadEmergent coronary procedurJapan
-
Claudia SpiesAvslutadOmskärelse, Meatotomy eller Distal Coronary Correction of HypospadiaTyskland
-
Tel-Aviv Sourasky Medical CenterAvslutadKonsekutiva ämnen som är lämpliga för en kranskärlssjukdom | Angioplastik av de Novo lesion(er) i Native Coronary | Artärer bör undersökas för behörighet. | Totalt antal 200 patienter som uppfyller urvalet | Kriterier och villig att underteckna det informerade samtycket | vara inskriven i provet.Israel
-
RenJi HospitalAvslutadST Segment Elevation Myokardinfarkt | Coronary Slow Flow FenomenKina
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AvslutadTidigare behandlat myelodysplastiskt syndrom | Myelodysplastiskt syndrom | Terapierelaterat myelodysplastiskt syndrom | Sekundärt myelodysplastiskt syndrom | Refraktärt högrisk myelodysplastiskt syndromFörenta staterna
-
National Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
Institut de Recherches Internationales ServierServier Bio-Innovation LLCHar inte rekryterat ännuMyelodysplastiska syndrom (MDS) | Hypometylerande medel (HMA) Naiva myelodysplastiska syndrom (MDS)
Kliniska prövningar på Bioresorbable scaffold (BRS)
-
R3 Vascular Inc.RekryteringKritisk extremitetsischemi | Kritisk nedre extremitetsischemi | Kritisk extremitetshotande ischemiAustralien
-
St. Louis UniversityAvslutadRekonstruktion av främre korsbandetFörenta staterna
-
Chinese Academy of SciencesAffiliated Hospital of Logistics University of CAPFOkänd
-
Chinese Academy of SciencesThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...OkändErektil dysfunktion | Rektal cancerKina
-
Cairo UniversityRekrytering
-
Shenzhen People's HospitalOkänd
-
Elixir Medical CorporationEuropean Cardiovascular Research CenterAvslutad
-
Bengtson CenterAllergan MedicalAvslutadÅterkommande ptos i bröstetFörenta staterna
-
Elixir Medical CorporationAvslutadKranskärlssjukdomNya Zeeland, Belgien
-
Elixir Medical CorporationAvslutadKranskärlssjukdomNya Zeeland, Belgien, Tyskland, Polen, Danmark, Brasilien